Corporate Support ISAL XIX 2025
The organizers of ACUTE LEUKEMIAS XIX (ISALXIX) wish to thank all corporate partners to actively for their support of the international symposium ACUTE LEUKEMIAS XIX, Munich, March 16-19, 2025.
The organizers highly value the partnerships and their important role that members of this community play by supporting the international symposium ACUTE LEUKEMIAS in their effort to provide hematologists with high quality educational sessions thus rendering all attendees the opportunity to discuss the most recent findings in basic research and results of clinical studies on the field of acute leukemias.
Corporate Support ISALXIX – 2025
SATELLITE SYMPOSIA I – V
S U N D A Y – March 16, 2025
16.45-17.45 SATELLITE SYMPOSIUM I (SAT I)
Industry sponsored Satellite (Daiichi Sankyo)
Lecture Hall III (Overflow Rooms: LHs IV+V)
AML Unpacked: Awareness, Management and Latest Trends in Fit Newly Diagnosed Patients
Meeting Objectives:
∎ Review the current treatment landscape for fit patients with newly diagnosed FLT3-mutated AML
∎ Discuss the assessment of fit patients with newly diagnosed AML, looking to novel targets on the horizon
16.45-16:50
Welcome and Introduction
L. Bullinger, Berlin, DE
16:50-17.10
K. Döhner, Ulm, DE. State of the Art: Treatment Landscape for Fit Patients with Newly Diagnosed FLT3-Mutated AML
17:10-17:30
P. Vyas, Oxford. UK. Hot Topics: Assessing Fit Patients with Newly Diagnosed AML – Novel Targets on the Horizon
17:30-17.45
Panel Discussion and Closing – All Faculty
M O N D A Y – March 17, 2025
16:30-17:30: SATELLITE SYMPOSIUM II (SAT II)
Industry sponsored Session (Otsuka Pharma GmbH)
Lecture Hall III (Overflow Rooms: LHs IV/V)
Managing Difficult Decisions in Unfit AML Patients in the Context of the New ELN 2024 Recommendations
16.30-16.50
L. Bullinger, Berlin, DE. Current and Future Treatment Options for Unfit AML Patients
16:50-17.05
E. Jost, Aachen, DE: How to Treat ELN 2024 Intermediate/Adverse-Risk Patients: Combination Therapy Beats HMA Monotherapy
17:05-17:25
W. Kirakosow, Mühlheim a.d.R., DE: How to Treat ELN 2024 Intermediate/Adverse-Risk Patients: Still Room for HMA Monotherapy?
17:25-17.30
Closing Remarks
18:00-19:00: SATELLITE SYMPOSIUM III (SAT III)
Industry sponsored Satellite (AbbVie Deutschland GmbH)
Lecture Hall III (Overflow Rooms: LHs IV/V)
Exploring Future Treatment Strategies for AML Patients
18:00-18:05
Welcome and Introduction/Chair:
L. Bullinger, Berlin, DE
18:05-18.25
Ch. Röllig, Dresden, DE: Treatment of IC-Ineligible AML Patients – How Can Novel Strategies Improve Clinical Results?
18:25-18:45
Ch. Craddock, Birmingham, UK: Reaching New Heights: Advancing Outcomes for Transplant Patients in AML
18:45-18.55
Panel Discussion and Q&A
All Faculty
18:55-19.00
Closing Remarks
L. Bullinger, Berlin, DE
T U E S D A Y – March 18, 2025
16:15-17:15: SATELLITE SYMPOSIUM IV (SAT IV)
Industry sponsored Satellite (Servier France)
Lecture Hall III (Overflow Rooms LHs IV+V)
Targeting IDH1 Mutations in Front Line AML for the Unfit Patient
16:15-16:20
Gail Roboz, New York, NY, USA: Emerging Induction Strategies in AML
16:20-16:30
Hartmut Doehner, Ulm, DE: Exploring Therapeutic Strategies for IDH1-Mutated Patients
16:30-16:40
Maria Teresa Voso, Rome, I: Molecular Testing- When and How?
16:40-16:50
Lars Fransecky, Kiel, DE: Clinical Case Presentation
16:50-17:00
Michael Kuehn, Mainz, DE: Shaping the Future of AML Care: Clinical Trials for Targeted Therapies
17:00-17:15
Questions and Discussion
All Faculty
17.45-18.45: SATELLITE SYMPOSIUM V (SAT V)
Industry sponsored Session (Amgen GmbH)
Lecture Hall III (Overflow Rooms LHs IV+V)
A New Era: Immunotherapy for Newly Diagnosed B-ALL
17:45-17:50
Welcome and Introduction
M. Subklewe, Munich, DE
17:50-18.15
N. Gökbuget, Frankfurt, DE: Immunotherapy in Frontline Treatment of Ph-negative and -positive B-ALL
18:15-18:40
M. Subklewe, Munich, DE: The Future: SC Application and New Indications
18:40-18.45
Closing Remarks
N. Gökbuget, Frankfurt, DE
MEET-THE-PROFESSOR SESSIONS I and II
M O N D A Y – March 17, 2025
13:00-13:45: MEET-THE-PROFESSOR SESSION (MTP I)
Industry sponsored Session (Astellas Pharma GmbH)
Lecture Hall III (Overflow Rooms: LHs IV/V)
13:00-13:20:
Ch. Röllig, Dresden DE: R/R FLT3m+ AML – Therapy: Today and in the Future
13:20-13:40:
F. Thol, Hannover, DE: Diagnostics in AML
13:40-13:45:
CLOSING REMARKS
T U E S D A Y – March 18, 2025
13:00-13:45: Meet-the-Professor Session (MTP II)
Industry sponsored Session (Jazz Pharmaceuticals)
Lecture Hall III (Overflow Rooms: LHs IV/V)
13:00-13:03:
Welcome and Introduction
L. Bullinger, Berlin, DE
13:03-13:08 :
L. Bullinger, Essen, DE: Long-Term Survival in Older Patients with Poor Prognosis:A Patient Case Study
13:08-13:28:
Th. Schroeder, Essen, DE: Optimizing Transplant Potential in Older Patients: What Does Real-World Data Tell Us?
13:28-13:43:
Audience Q & A
13:43-13:45:
CLOSING REMARKS
L. Bullinger, Berlin, DE